Company Profile
Delcath Systems Stock Price, News & Analysis
- Ticker:
- DCTH
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
15.47 USD (+22.49%)
Close
Last updated: August 6, 2026
364M USD
Market cap
Why the stock is moving
Following the latest company update, “Delcath Systems Reports Second Quarter 2026 Results and Business Highlights”, DCTH closed up 22.5% at $15.47 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Interventional Oncology
Delcath Systems develops liver-directed therapies for primary and metastatic liver cancers. Its technology isolates hepatic circulation so high-dose chemotherapy can be delivered to the liver while limiting systemic exposure.
HEPZATO KIT
HEPZATO KIT combines melphalan with the company's percutaneous hepatic-perfusion system. It is approved in the United States for selected adults with unresectable hepatic-dominant metastatic uveal melanoma. CHEMOSAT is the European commercial version of Delcath's hepatic-delivery platform. The company supports adoption through treatment-center activation, clinician training and procedure-based consumable sales.
Future catalysts
Delcath's story is still centered on the liver-cancer treatment platform and the company's commercial execution around it. The preliminary results suggest the product is moving through a real operating phase now, which means the next update should tell us more about adoption than about early development risk.
Recent news
- 01
Delcath Systems Reports Second Quarter 2026 Results and Business Highlights
Source: Delcath Systems
- 02
Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference
Source: Delcath Systems
- 03
Delcath Systems to Host Second Quarter 2026 Earnings Call
Source: Delcath Systems
- 04
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Delcath Systems
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Delcath Systems (DCTH)?
Delcath Systems (DCTH) most recently closed at 15.47 USD, a +22.49% move versus the previous session.
What is the market cap of Delcath Systems (DCTH)?
Delcath Systems currently has a market capitalization of 364M USD on BioPharmSignal.
What does Delcath Systems do?
Interventional Oncology Delcath Systems develops liver-directed therapies for primary and metastatic liver cancers. Its technology isolates hepatic circulation so high-dose chemotherapy can be delivered to the liver while limiting systemic exposure. HEPZATO KIT HEPZATO KIT combines melphalan with the company's percutaneous hepatic-perfusion system. It is...
On which exchange is DCTH stock listed?
Delcath Systems (DCTH) is associated with NASDAQ, United States, Biopharma.
What is Interventional?
Interventional Oncology Delcath Systems develops liver-directed therapies for primary and metastatic liver cancers.
Which conditions is Delcath Systems targeting with Interventional?
Delcath Systems is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Delcath Systems describe recent progress with Interventional?
Delcath's story is still centered on the liver-cancer treatment platform and the company's commercial execution around it. The preliminary results suggest the product is moving through a real operating phase now, which means the next update should tell us more about adoption than about early development risk.
What is Oncology?
Interventional Oncology Delcath Systems develops liver-directed therapies for primary and metastatic liver cancers.